Came from the AFR article... so why is this company valued at $300m+ yet, from my understanding, hasn't actually commenced FDA clinical trials? Is the pre clinical data that impressive that the likelihood of success is so high?
I have literally had a quick glance at it so I could be incorrect with my interpretation, just seems like a high valuation for a company that hasn't yet begun FDA trials...
DurAVR and AVR in the AFR today! (Plus Bioshares), page-3
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.49 |
Change
0.490(4.08%) |
Mkt cap ! $264.0M | |||
| Open | High | Low | Value | Volume |
| $12.11 | $12.49 | $11.50 | $155.8K | 13.16K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 175 | $11.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.49 | 77 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| AVR (ASX) Chart |